Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking ...

The pharmaceutical company is evaluating all options to increase its presence in therapy areas, including in-licensing ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Syndeio Biosciences today announced its launch to pioneer precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company’s ...

The next-gen immunotherapies market is evolving with biotech advances, rising cancer cases, new therapies, funding, and ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

Patients treated with teduglutide had significant reductions in parenteral nutrition and/or IV fluid requirements over 10 ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Across the board, oncologists are navigating a fast-changing landscape while managing full patient loads, reimbursement ...

Oral antidiabetic drugs play an important role in the management of type 2 diabetes and were developed to regulate blood glucose levels in individuals who are resistant to the effects of insulin or ...